StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $23.10 | $20.56 | -11.00% | 6.9M |
| 05-18 | $20.95 | $20.63 | -1.53% | 3.3M |
| 05-19 | $20.40 | $20.30 | -0.49% | 1.9M |
| 05-20 | $21.08 | $21.08 | +0.00% | 3.4M |
| 05-21 | $20.99 | $21.62 | +3.00% | 2.6M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $62.38M | $62.38M | $8.57M |
Operating Income | $-48.77M | $-111.29M | $-69.42M | $-83.50M |
Net Income | $-45.51M | $-101.59M | $-62.84M | $-38.85M |
EPS (Diluted) | $-0.32 | $-0.87 | $-0.57 | $-0.71 |
Total Assets | $435.79M | $398.69M | $210.14M | $237.89M |
Total Liabilities | $44.29M | $52.51M | $50.10M | $102.94M |
Cash & Equivalents | $157.83M | $112.28M | $58.34M | $39.27M |
Free Cash Flow OCF − CapEx | $-44.36M | $-139.93M | $-109.99M | $-78.89M |
Shares Outstanding | 144.16M | 135.94M | 111.57M | 110.87M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.